Organoid-Based Phenotypic Screening

BOC Sciences, leveraging its advanced organoid technology platform, has developed a systematic phenotypic screening service that comprehensively covers key stages such as early drug discovery, mechanism research, personalized medicine, and toxicity assessment. We possess a rich repository of patient-derived organoid (PDO) models, a multi-organ organoid biobank, as well as high-throughput screening and high-content imaging capabilities, enabling highly accurate simulation of complex disease microenvironments and multidimensional phenotypic analysis. Through flexible and customized screening strategies and data analysis systems, BOC Sciences provides customers with efficient, precise, and translational organoid-based drug screening solutions.

Organoid-Based Phenotypic Screening Services from BOC Sciences

The organoid phenotypic screening platform developed by BOC Sciences integrates organoid culture techniques, high-content screening (HCS) systems, automated liquid handling, and AI-driven data analysis algorithms to provide a complete service workflow from model construction to compound screening and mechanism validation.

Multi-Organ Organoid Screening Library (Organoid Biobank)

• Includes organoid libraries covering the digestive, respiratory, urinary, and nervous systems, as well as various solid tumors.
• Organoid models in the library include those derived from liver, intestine, lung, stomach, pancreas, kidney, prostate, and other organs or tissues.
• All organoid models are molecularly characterized to ensure data comparability and model stability.
• Normal tissue-derived organoids can be used for toxicity evaluation and selectivity testing.

Personalized Compound Library Design and Screening

• Based on the client's target pathway or mechanism, we assist in customizing exclusive small molecule or natural product libraries.
• Literature analysis and database-integrated screening can be conducted based on specific targets, structural features, and functional categories.
• Screening support is available for various library sizes (small:<500; medium:="" large:="">5000 compounds).
• Integrated screening and mechanism validation workflows can be conducted using organoid models.
• Screening outputs include detailed phenotypic change data, IC50 calculations, selectivity index, and more.

High-Throughput 3D Screening

• We are equipped with advanced automated high-throughput screening systems (HTS).
• High-precision automated liquid handling.
• Standardized construction of 3D organoid culture systems.
• High-content screening systems (HCS) for image acquisition and analysis.
• Multi-parameter phenotypic readouts (e.g., morphology, fluorescent labeling, cell death, DNA damage, etc.).

Toxicology Screening and Safety Evaluation

• Use of normal tissue-derived organoids (e.g., liver, intestinal, kidney organoids) as models to evaluate the toxicity response of candidate drugs.
• Multi-parameter toxicity assessment indicators: decreased cell viability, induced apoptosis, tissue damage, metabolic disorders, etc.
• Capable of studying acute toxicity, chronic exposure models, dose-response relationships, and time-dependent effects.
• Comparative analysis with tumor organoids provided to calculate therapeutic window and selective toxicity index.
• Transcriptomics and proteomics analysis can be combined to investigate toxicity-related pathways and targets, supporting early candidate optimization.

Comprehensive Organoid Library for Phenotypic Screening

BOC Sciences has established a fully functional organoid model library covering multiple tissue origins, including the digestive, respiratory, nervous, and urinary systems, involving various disease types such as liver cancer, lung cancer, breast cancer, pancreatic cancer, colorectal cancer, and neurodegenerative diseases. The platform integrates PDO, induced pluripotent stem cell (iPSC)-derived organoids, and normal tissue-derived models to meet diverse screening needs such as efficacy evaluation, toxicity analysis, and personalized drug response studies, widely applicable to oncology, rare diseases, and precision medicine.

Applications of Organoid-Based Phenotypic Screening

Anti-Tumor Drug Screening and Target Validation

Organoids can highly simulate the three-dimensional structure and genetic mutation characteristics of tumor tissues, making them suitable for screening chemotherapy drugs, targeted agents, and immunotherapies for various cancer types. By monitoring phenotypic changes such as proliferation inhibition, apoptosis induction, and stemness elimination, candidate drug activity evaluation and preliminary mechanism validation can be achieved, accelerating the discovery and optimization of new anti-cancer drugs.

Personalized Medicine and Precision Therapy

Organoids can be directly constructed from patient tissues, retaining individual tumor or tissue genetic backgrounds and drug sensitivity differences. By conducting drug phenotypic screening on patient-specific organoids, responses to various treatment regimens can be predicted, providing personalized medication references for clinicians and serving as a key technological support for precision medicine strategies.

Rare and Genetic Disease Model Research

For rare genetic disorders or congenital metabolic diseases, organoids can be constructed as pathological models via stem cell induction or gene editing. Drug phenotypic screening on these models helps identify potential therapeutic candidates, especially in disease areas lacking animal models or clinical samples, providing efficient solutions for orphan drug development.

Toxicology and Safety Assessment

Organoids structurally and functionally resemble in vivo tissues more closely, and can be used to assess toxicity in organs such as the liver, kidney, and heart, addressing the limitations of traditional 2D cell models. Observing phenotypic changes like apoptosis, injury markers, and metabolic enzyme expression supports early identification of drug toxicity risks and optimization of candidate compound screening criteria.